Antidepressant effect of the interaction of fluoxetine with granisetron

Abstract

Selective serotonin reuptake inhibitors (SSRIs) may produce digestive side effects such as nausea and vomiting, diarrhoea and decreased appetite. These side effects are determined by the increase in serotonin availability at 5-HT3 receptors. Granisetron, a serotonin 5-HT3 receptor antagonist, is expected to antagonize the digestive adverse effects of serotonin reuptake inhibitors, but the question is to what extent granisetron influences the antidepressant effect of these substances. The aim of this study was to determine the dose of fluoxetine that has an antidepressant effect in the Porsolt test, and the interaction between fluoxetine and granisetron with respect to the antidepressant effect in this test. In experiment 1, fluoxetine was antidepressant only at 20 mg/kg body weight (bw). In experiment 2, granisetron 1 mg/kg bw had a statistically significant antidepressant effect vs. control. Fluoxetine 20 mg/kg bw associated with a small dose of granisetron (0.1 mg/kg bw) produced a significant antidepressant effect vs. control. This shows that low doses of granisetron associated to fluoxetine might produce a significant antidepressant effect, suggesting a potentiation between these two drugs used in sub-effective antidepressant doses. In conclusion, in our experimental conditions, we can assume that granisetron in low doses could be used to combat intestinal transit disorders produced by SSRI antidepressants. These low doses are preferred, because they increase the antidepressant effect of these SSRIs.

N-acetylcysteine Alleviates Depression through Up-regulation of Synaptophysin, Inhibition of Reactivity Astrocytes, and Anhedonia in the Forced Swim Test Animal Model

“…Fluoxetine however, decreased the immobility time, which supports previous studies (Abdel-Salam et al 2013). Furthermore, fluoxetine increased mobility time in the FST (Costescu et al 2019), which the present study aligns. The potency of fluoxetine in the FST is based on its ability as a selective serotonin reuptake inhibi- tor, demonstrated in alleviating behavioural depression, and possibly due to its ability to suppress cholinergic activities in the nucleus accumbens, or by inhibition of noradrenaline and dopamine reuptake.…”

Program for education and enrichment of relational skills (PEERS) training for social skills and depressed mood intervention in young adult with depression: Study protocol for a randomized controlled trial

“…Considering that the first onset of action of antidepressants is between 2 and 4°weeks ( 46 ), We, therefore, chose to collect the subjects’ depression scores at three-time points: baseline, week 3 of the intervention and week 6 of the intervention. The scales were selected based on clinical applicability and reliability to dynamically assess the efficacy of the localized PEERS training.…”

Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence

“…Granisetron is an antagonist of this receptor and its activity can alleviate gastrointestinal disorders associated with the use of SSRIs. At low doses, an increase in the antidepressant action of fluoxetine is also observed when administered in conjunction with granisetron [ 114 ]. A previous study has shown that other antidepressants such as imipramine, phenelzine, and iproniazid are able to inhibit the serotonergic current mediated by the 5-HT 3 receptor, blocking its action.…”